MY171048A - Pharmaceutical composition for preventing or treating amyloid beta peptide-associated diseases or conditions - Google Patents

Pharmaceutical composition for preventing or treating amyloid beta peptide-associated diseases or conditions

Info

Publication number
MY171048A
MY171048A MYPI2014001777A MYPI2014001777A MY171048A MY 171048 A MY171048 A MY 171048A MY PI2014001777 A MYPI2014001777 A MY PI2014001777A MY PI2014001777 A MYPI2014001777 A MY PI2014001777A MY 171048 A MY171048 A MY 171048A
Authority
MY
Malaysia
Prior art keywords
preventing
conditions
pharmaceutical composition
associated diseases
amyloid beta
Prior art date
Application number
MYPI2014001777A
Other languages
English (en)
Inventor
Hang-Ching Lin
Muh-Hwan Su
Young-Ming Huang
jing-jing Tang
Original Assignee
Sinphar Tian Li Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sinphar Tian Li Pharmaceutical Co Ltd filed Critical Sinphar Tian Li Pharmaceutical Co Ltd
Publication of MY171048A publication Critical patent/MY171048A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
    • A23G4/00—Chewing gum
    • A23G4/06—Chewing gum characterised by the composition containing organic or inorganic compounds
    • A23G4/10—Chewing gum characterised by the composition containing organic or inorganic compounds characterised by the carbohydrates used, e.g. polysaccharides
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Preparation or treatment thereof
    • A23L2/52—Adding ingredients
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/64—Orobanchaceae (Broom-rape family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Nutrition Science (AREA)
  • Microbiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Inorganic Chemistry (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MYPI2014001777A 2011-12-16 2012-12-17 Pharmaceutical composition for preventing or treating amyloid beta peptide-associated diseases or conditions MY171048A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161576367P 2011-12-16 2011-12-16

Publications (1)

Publication Number Publication Date
MY171048A true MY171048A (en) 2019-09-23

Family

ID=48580733

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2014001777A MY171048A (en) 2011-12-16 2012-12-17 Pharmaceutical composition for preventing or treating amyloid beta peptide-associated diseases or conditions

Country Status (11)

Country Link
US (1) US20150087606A1 (https=)
EP (1) EP2792361B1 (https=)
JP (1) JP6134331B2 (https=)
KR (1) KR102048289B1 (https=)
CN (1) CN103156867B (https=)
AU (1) AU2012350437B2 (https=)
CA (1) CA2859227C (https=)
MY (1) MY171048A (https=)
SG (1) SG11201403265VA (https=)
TW (1) TWI488630B (https=)
WO (1) WO2013087042A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015154721A1 (zh) * 2014-04-10 2015-10-15 杏辉天力（杭州）药业有限公司 异类叶升麻苷衍生物及其制造方法与用途
TWI650131B (zh) 2014-07-03 2019-02-11 杏輝藥品工業股份有限公司 管花肉蓯蓉萃取物之用於製備保護眼部細胞之藥品或食品用途
CN104922137B (zh) * 2015-06-04 2018-07-31 苏州大学 苯乙醇苷类化合物Torenoside B的新用途
KR102018085B1 (ko) * 2017-12-06 2019-09-04 김좌진 악테오사이드를 함유하는 뇌종양 치료 및 전이 억제용 약학 조성물
KR102135148B1 (ko) * 2019-08-28 2020-07-20 김좌진 악테오사이드를 함유하는 뇌종양 치료 및 전이 억제용 약학 조성물
CN110812375A (zh) * 2019-12-12 2020-02-21 中国海洋大学 一种老鼠簕中苯乙醇苷类提取物及其制备方法与作为抗肝损伤药物的应用
CN111632058A (zh) * 2020-06-24 2020-09-08 新疆医科大学 毛蕊花糖苷在制备预防和治疗神经退行性疾病药物中的应用
CN112225766A (zh) * 2020-10-27 2021-01-15 杏辉天力（杭州）药业有限公司 一种由肉苁蓉萃取物中富集及分离苯乙醇苷类化合物的方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100500584B1 (ko) * 2002-08-12 2005-07-12 경희대학교 산학협력단 신경성장인자와 유사 작용을 갖는 육종용 추출물 및 이를함유하는 조성물
KR100514076B1 (ko) * 2003-01-10 2005-09-13 주식회사 엘컴사이언스 페닐에타노이드 유도체를 포함하는 퇴행성 뇌신경계질환의 예방 및 치료용 조성물
TW200416036A (en) * 2003-02-18 2004-09-01 Sinphar Pharmaceutical Co Ltd Medicinal preparation containing phenylethanoid glycosides extracted from herbaceous plant, cistanche tubulosa (schenk.) wight, process of making the same, and uses of the same
CN1268341C (zh) * 2003-03-04 2006-08-09 杏辉天力（杭州）药业有限公司 来源于管花肉苁蓉的含有苯乙醇苷的制剂及其制备方法和用途
CN100345857C (zh) * 2004-07-16 2007-10-31 北京华医神农医药科技有限公司 一种从肉苁蓉药材中提取、分离松果菊苷的方法
EP1736167B1 (en) * 2005-06-20 2018-03-21 I.R.B. Istituto Di Ricerche Biotecnologiche S.r.l. Extracts obtained from cell line cultures from Syringa vulgaris IRB-SV25/B (DMS:16857), their preparation and use
JP5410683B2 (ja) 2008-02-19 2014-02-05 学校法人近畿大学 カンカニクジュヨウから得られる肝保護剤及び抗ＴＮＦ−α作用剤
CN101411753B (zh) * 2008-12-04 2012-02-29 闫明 列当总苷在制备抗老年痴呆的药物中的应用
CN101797307B (zh) * 2010-04-09 2011-08-10 广州中医药大学 一种含苯乙醇苷的枇杷叶紫珠提取物及其制备方法
TWI486162B (zh) * 2010-06-16 2015-06-01 Sinphar Pharmaceutical Co Ltd 異類葉升麻苷或其醫藥學上可接受之鹽於抑制澱粉樣β肽生成、累積或聚集、以及製備預防或治療澱粉樣β肽相關疾病或狀況的藥物之用途
CN102670631B (zh) * 2011-12-01 2013-07-31 河南科技大学 一种四楞麻总苯乙醇苷组合物、制备方法及应用

Also Published As

Publication number Publication date
CA2859227C (en) 2019-01-22
EP2792361A4 (en) 2015-05-13
EP2792361B1 (en) 2019-03-27
AU2012350437B2 (en) 2017-06-29
KR20150002576A (ko) 2015-01-07
CA2859227A1 (en) 2013-06-20
TWI488630B (zh) 2015-06-21
JP6134331B2 (ja) 2017-05-24
JP2015500300A (ja) 2015-01-05
CN103156867B (zh) 2019-04-30
EP2792361A1 (en) 2014-10-22
CN103156867A (zh) 2013-06-19
SG11201403265VA (en) 2014-09-26
TW201325597A (zh) 2013-07-01
AU2012350437A1 (en) 2014-07-31
KR102048289B1 (ko) 2020-01-08
US20150087606A1 (en) 2015-03-26
WO2013087042A1 (zh) 2013-06-20

Similar Documents

Publication Publication Date Title
MY171048A (en) Pharmaceutical composition for preventing or treating amyloid beta peptide-associated diseases or conditions
GB201118656D0 (en) New compounds
NZ702663A (en) Nuclear transport modulators and uses thereof
PH12013502118A1 (en) Aryl-or heteroaryl-substituted benzene compounds
MX344530B (es) Compuestos de benceno substituido.
IL231536A (en) Indazole-3-carboxamides, pharmaceuticals containing them and their use in the treatment of diseases
MX2013008851A (es) Composiciones y metodos para el tratamiento de inflamacion cronica y enfermedades inflamatorias.
IN2014MN00987A (https=)
MX356728B (es) Combinación farmacéutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2.
MX349224B (es) Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa.
EA032271B9 (ru) Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний
MX2013013649A (es) Compuestos de quinona para tratar enfermedades mediadas por ape1.
GB2497453B8 (en) Pharmaceutical composition and methods of treating and preventing the diseases caused by HIV or associated with HIV
MX367926B (es) Composicion farmaceutica para liberacion sostenida de lanreotida.
TN2014000046A1 (en) Substituted 3-(biphenyl-3-yl)-4-hydroxy-8-methoxy-1-azaspiro[4.5]dec-3-en-2-one
MX342976B (es) Uso de melatonina para el tratamiento y/o prevencion de la mucositis.
PL2874600T3 (pl) Kompozycja farmaceutyczna do leczenia chrypki lub bólów gardła.
MX364528B (es) Witanólidos útiles para el tratamiento de enfermedades neurodegenerativas.
EP4385563A3 (en) Dosage forms and therapeutic uses l-4-chlorokynurenine
NZ707773A (en) Methods of treating liver diseases
MX2013012967A (es) Composicion de miel con l-alanil-l-glutamina.
PH12013501896A1 (en) Use of a sprayable composition comprising ambroxol
GB201115977D0 (en) Neurodevelopmental disorders
UA115079C2 (uk) Сполуки як інгібітори діацилгліцеринацилтрансферази
BR112014015193A8 (pt) composição enriquecida com glicoproteína como um aditivo para alimento e/ou ração e/ou como um agente terapêutico